Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway

Hepatocellular carcinoma (HCC) is the most common pathological type of primary hepatic carcinoma. This study investigated the effects of ginsenoside Rg3 (Rg3) and sorafenib (SFN) combination therapy on HCC progression. The HCC-related data were obtained from TCGA database, and the data of HK2 mRNA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Qi, Ren, Yuan, Zheng, Xia, Yang, Sufang, Lu, Tingting, Ji, Hongyao, Hua, Haiqing, Shan, Kuizhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275937/
https://www.ncbi.nlm.nih.gov/pubmed/35719058
http://dx.doi.org/10.1080/21655979.2022.2074616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275937/
https://www.ncbi.nlm.nih.gov/pubmed/35719058
http://dx.doi.org/10.1080/21655979.2022.2074616

Ejemplares similares